[go: up one dir, main page]

NO20010389D0 - Modulering av multippel linje-kinaseproteiner - Google Patents

Modulering av multippel linje-kinaseproteiner

Info

Publication number
NO20010389D0
NO20010389D0 NO20010389A NO20010389A NO20010389D0 NO 20010389 D0 NO20010389 D0 NO 20010389D0 NO 20010389 A NO20010389 A NO 20010389A NO 20010389 A NO20010389 A NO 20010389A NO 20010389 D0 NO20010389 D0 NO 20010389D0
Authority
NO
Norway
Prior art keywords
methods
compound
protein
lineage kinase
kinase protein
Prior art date
Application number
NO20010389A
Other languages
English (en)
Other versions
NO20010389L (no
Inventor
Anna Maroney
Kevin M Walton
Craig A Dionne
Nicola Neff
Jr Ernest Knight
Marcie A Glicksman
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20010389D0 publication Critical patent/NO20010389D0/no
Publication of NO20010389L publication Critical patent/NO20010389L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
NO20010389A 1998-08-26 2001-01-23 Modulering av multippel linje kinase proteiner NO20010389L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9798098P 1998-08-26 1998-08-26
PCT/US1999/018864 WO2000013015A1 (en) 1998-08-26 1999-08-18 Modulating multiple lineage kinase proteins

Publications (2)

Publication Number Publication Date
NO20010389D0 true NO20010389D0 (no) 2001-01-23
NO20010389L NO20010389L (no) 2001-04-02

Family

ID=22266038

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010389A NO20010389L (no) 1998-08-26 2001-01-23 Modulering av multippel linje kinase proteiner

Country Status (24)

Country Link
EP (1) EP1105728B1 (no)
JP (1) JP2002523780A (no)
KR (1) KR100700028B1 (no)
CN (3) CN1589788A (no)
AT (1) ATE293254T1 (no)
AU (1) AU765637B2 (no)
BG (1) BG105360A (no)
BR (1) BR9913190A (no)
CA (1) CA2339539A1 (no)
CZ (1) CZ2001701A3 (no)
DE (1) DE69924738T2 (no)
DK (1) DK1105728T3 (no)
EA (2) EA200500934A1 (no)
ES (1) ES2241316T3 (no)
HU (1) HUP0103079A3 (no)
NO (1) NO20010389L (no)
NZ (1) NZ509612A (no)
PL (1) PL346246A1 (no)
PT (1) PT1105728E (no)
SK (1) SK2542001A3 (no)
TR (2) TR200400635T2 (no)
UA (1) UA74772C2 (no)
WO (1) WO2000013015A1 (no)
ZA (1) ZA200100835B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
IL154311A0 (en) * 2000-08-11 2003-09-17 Cephalon Inc Modulating multiple lineage kinase proteins
AR035971A1 (es) 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2003052395A (ja) * 2001-08-09 2003-02-25 Japan Tissue Engineering:Kk 移植適正判定方法
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
CA2711585A1 (en) * 2008-02-04 2009-08-13 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
AU2015202365B2 (en) * 2008-10-22 2016-11-24 Genentech, Inc. Modulation of axon degeneration
KR20110081862A (ko) 2008-10-22 2011-07-14 제넨테크, 인크. 축삭 변성의 조절
AU2010310589A1 (en) * 2009-10-22 2012-05-10 Genentech, Inc. Modulation of axon degeneration
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
US9539259B2 (en) 2012-05-23 2017-01-10 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
CN109060472A (zh) * 2018-07-20 2018-12-21 上海市农业科学院 一种适于荧光染色的草菇菌褶组织切片的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions

Also Published As

Publication number Publication date
HK1037722A1 (en) 2002-02-15
ZA200100835B (en) 2002-06-26
EA006648B1 (ru) 2006-02-24
NO20010389L (no) 2001-04-02
CN1314999A (zh) 2001-09-26
PL346246A1 (en) 2002-01-28
EP1105728A1 (en) 2001-06-13
HUP0103079A2 (hu) 2001-12-28
PT1105728E (pt) 2005-07-29
CN1206535C (zh) 2005-06-15
CN1589788A (zh) 2005-03-09
TR200400635T2 (tr) 2005-10-21
EA200500934A1 (ru) 2006-04-28
DE69924738T2 (de) 2006-03-02
EP1105728B1 (en) 2005-04-13
HUP0103079A3 (en) 2004-03-01
BG105360A (bg) 2001-10-31
ES2241316T3 (es) 2005-10-16
CN1879617A (zh) 2006-12-20
NZ509612A (en) 2003-10-31
SK2542001A3 (en) 2002-06-04
AU765637B2 (en) 2003-09-25
WO2000013015A1 (en) 2000-03-09
CZ2001701A3 (cs) 2002-04-17
DK1105728T3 (da) 2005-08-08
WO2000013015A8 (en) 2000-05-11
CA2339539A1 (en) 2000-03-09
AU5679399A (en) 2000-03-21
BR9913190A (pt) 2001-12-11
JP2002523780A (ja) 2002-07-30
KR100700028B1 (ko) 2007-03-27
KR20010103573A (ko) 2001-11-23
EA200100278A1 (ru) 2002-06-27
DE69924738D1 (de) 2005-05-19
TR200100589T2 (tr) 2001-07-23
ATE293254T1 (de) 2005-04-15
UA74772C2 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
NO20010389D0 (no) Modulering av multippel linje-kinaseproteiner
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ZA988797B (en) Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds.
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
ATE391177T1 (de) Zusammensetzungen und methoden zur modulierung der zellulären aktivität von nf-kappab
ATE301192T1 (de) Verwendung von neuronalem apoptose- inhibitorprotein
AU2002248180A1 (en) Non-apoptotic forms of cell death and methods of modulation
WO2002014536A3 (en) Odulating multiple lineage kinase proteins
ATE506073T1 (de) Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
EP1121128A4 (en) METHOD FOR MODULATING THE FUNCTIONAL ACTIVITY OF THE ION CHANNEL
DE60007864D1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
DE69738945D1 (de) Rken
ATE272406T1 (de) Prognose von ptp lar vermittelten krankheiten
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application